Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Incorporated on 11th August 1999, ARIUS Research is a biotechnology company dedicated to personalising cancer therapy through the discovery and development of novel anticancer monoclonal antibodies (MAbs). ARIUS has built a proprietary technology platform, FunctionFIRST, that rapidly and cost-effectively identifies powerful MAbs targeting a variety of cancer indications. This Ab generation engine has enabled ARIUS to assemble a growing pipeline of over 200 functional MAbs, which may be used for commercial collaborations, out-licensing or in-house development.

The long-term vision of ARIUS is to deliver personalised therapy by matching multiple Abs to the distinct antigenic characteristics of each patient's tumour cells thereby increasing efficacy and avoiding side effects.

Current research is focused on breast, lung, prostate and ovarian cancers. Working independently and through partnerships, ARIUS intends to expand its research into related areas, including other gastrointestinal cancers, ovarian and prostate cancers.